Table 2.
Genomic Characteristics - Univariable analysis of observed response, progression-free survival, and overall survival.
| Alteration | ORR | p-value | mOS: HR (95% CI) | p-value | mPFS: HR (95% CI) | p-value | |
|---|---|---|---|---|---|---|---|
|
ARID1A
(n = 8) |
Present | 50% | 0.71 | 1.39 (0.47-4.18) | 0.55 | 1.21 (0.49-3.21) | 0.63 |
| Absent | 42% | ||||||
|
CDKN2A
(n = 11) |
Present | 36% | 0.48 | 1.42 (0.49-4.12) | 0.52 | 1.78 (0.72-4.40) | 0.22 |
| Absent | 50% | ||||||
|
CDKN2B
(n = 11) |
Present | 36% | 0.48 | 1.42 (0.49-4.12) | 0.52 | 1.78 (0.72-4.40) | 0.22 |
| Absent | 50% | ||||||
|
ERBB2
(n = 5) |
Present | 60% | 0.44 | 0.21 (0.03-1.62) | 0.14 | 0.53 (0.15-1.81) | 0.31 |
| Absent | 41% | ||||||
|
KDM6A
(n = 6) |
Present | 83% | 0.03 | 0.68 (019-2.45) | 0.56 | 0.85 (0.31-2.35) | 0.75 |
| Absent | 33% | ||||||
|
KM2TD
(n = 3) |
Present | 67% | 0.41 | 0.47 (0.06-3.63) | 0.47 | 0.72 (0.16-3.13) | 0.66 |
| Absent | 42% | ||||||
|
MDM2
(n = 3) |
Present | 100% | 0.04 | 0.79 (0.18-3.61) | 0.77 | 0.85 (0.25 -2.96) | 0.80 |
| Absent | 38% | ||||||
|
MTAP
(n = 3) |
Present | 67% | 0.95 | 0.52 (0.07-2.96) | 0.52 | 2.56 (0.69-9.55) | 0.16 |
| Absent | 42% | ||||||
|
PIK3CA
(n = 7) |
Present | 43% | 0.92 | 0.73 (0.20-2.62) | 0.63 | 0.94 (0.34-2.61) | 0.90 |
| Absent | 45% | ||||||
|
RB1
(n = 4) |
Present | 75% | 0.18 | 0.93 (0.21-4.22) | 0.93 | 0.93 (0.27-3.23) | 0.91 |
| Absent | 39% | ||||||
|
STAG2
(n = 3) |
Present | 67% | 0.95 | 0.63 (0.08-4.84) | 0.66 | 1.0 (0.23-4.38) | 0.99 |
| Absent | 42% | ||||||
|
TERT
(n = 20) |
Present | 50% | 0.33 | 0.52(0.16-1.72) | 0.28 | 0.59 (0.21-1.67) | 0.32 |
| Absent | 29% | ||||||
|
TP53
(n = 8) |
Present | 88% | <0.01 | 0.26 (0.06-1.18) | 0.08 | 0.34 (0.11-1.02) | 0.05 |
| Absent | 26% | ||||||
|
TP53/MDM2
(n=11) |
Present | 91% | <0.01 | 0.30 (0.09-0.99) | 0.05 | 0.34 (0.13-0.90) | 0.03 |
| Absent | 13% | ||||||
n is the number of patients with the alterations in a specific gene.Bold values indicate that the statistical significance was met.